MedTrace Logo

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

NCT07076680 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-11-28

No results posted yet for this study

Summary

The goal of this observational study is to learn about the safety and effectiveness of people with advanced breast cancer that is hormone receptor-positive (HR+), HER2-negative (HER2-).

Participants will:

Allow researchers to collect medical data during routine care

Be followed for signs of treatment effectiveness and any medical problems that happen while taking the drug

Conditions

  • Breast Cancer Metastatic
  • HR+/HER2- Advanced Breast Cancer

Sponsors & Collaborators

  • SciClone Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Jianli Zhao, Doctor · Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2027-02-01
Completion
2027-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07076680 on ClinicalTrials.gov